Overview
flowchart TD
Olfactory_Mucosa__Blood_and_Ur["Olfactory Mucosa, Blood and Urine for Identifica"]
Olfactory_Mucosa__Blood_and_Ur["multi-modal"]
Olfactory_Mucosa__Blood_and_Ur -->|"related to"| Olfactory_Mucosa__Blood_and_Ur
style Olfactory_Mucosa__Blood_and_Ur fill:#81c784,stroke:#333,color:#000
Olfactory_Mucosa__Blood_and_Ur["biomarker"]
Olfactory_Mucosa__Blood_and_Ur -->|"related to"| Olfactory_Mucosa__Blood_and_Ur
style Olfactory_Mucosa__Blood_and_Ur fill:#81c784,stroke:#333,color:#000
Olfactory_Mucosa__Blood_and_Ur["study"]
Olfactory_Mucosa__Blood_and_Ur -->|"related to"| Olfactory_Mucosa__Blood_and_Ur
style Olfactory_Mucosa__Blood_and_Ur fill:#81c784,stroke:#333,color:#000
style Olfactory_Mucosa__Blood_and_Ur fill:#4fc3f7,stroke:#333,color:#000
This multi-modal biomarker study investigates the use of olfactory mucosa, blood, and urine samples for early identification of neurodegenerative disorders including Parkinson's disease (PD), Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and related conditions["@nct"]. The study recognizes that olfactory dysfunction is one of the earliest and most common features of neurodegenerative diseases, often predating motor symptoms by years, and seeks to develop sensitive biomarker panels for early detection.
...Overview
Mermaid diagram (expand to render)
This multi-modal biomarker study investigates the use of olfactory mucosa, blood, and urine samples for early identification of neurodegenerative disorders including Parkinson's disease (PD), Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and related conditions["@nct"]. The study recognizes that olfactory dysfunction is one of the earliest and most common features of neurodegenerative diseases, often predating motor symptoms by years, and seeks to develop sensitive biomarker panels for early detection.
The recognition that smell dysfunction precedes motor symptoms in synucleinopathies by many years has generated intense interest in developing olfactory-based diagnostic tools. This study represents a comprehensive approach to multi-analyte biomarker detection across different biological compartments, aiming to identify early detection markers that could enable disease-modifying interventions before irreversible neuronal loss occurs.
Study Details
| Field | Value |
|-------|-------|
| NCT ID | NCT06846658 |
| Status | Recruiting |
| Study Type | Observational |
| Conditions | Parkinson's Disease, PSP, MSA, Atypical Parkinsonism, Healthy Controls |
| Sample Types | Olfactory mucosa, Blood, Urine |
| Primary Outcome | Diagnostic accuracy of multi-analyte biomarker panel |
| Secondary Outcomes | Sensitivity by disease stage, correlation with clinical measures |
Scientific Rationale
Olfactory Dysfunction as a Window to the Brain
The olfactory system provides a unique window into central nervous system pathology for several reasons[@hawkes1997][@lewitt2015]:
Direct anatomical connection: The olfactory tract projects directly from the olfactory bulb to the brain without a blood-brain barrier
Vulnerable neurons: Olfactory receptor neurons are exposed to environmental toxins and undergo continuous regeneration
Early involvement: The olfactory bulb is affected early in many neurodegenerative diseases
Accessible sampling: Olfactory mucosa can be sampled with minimally invasive proceduresOlfactory Dysfunction in Parkinson's Disease
Hyposmia (reduced sense of smell) occurs in over 90% of Parkinson's disease patients, making it one of the most prevalent non-motor symptoms[@hawkes1997]. Critically, olfactory dysfunction often precedes motor symptoms by 5-10 years:
- Idiopathic anosmia: Many patients diagnosed with idiopathic smell loss later develop PD
- Smell testing sensitivity: UPSIT (University of Pennsylvania Smell Identification Test) scores distinguish PD patients from controls with high sensitivity
- Prodromal markers: Olfactory dysfunction is included in proposed prodromal PD criteria
- Progression correlation: Smell loss correlates with disease severity and progression[@zhou2023]
Olfactory Dysfunction in Progressive Supranuclear Palsy
Olfactory dysfunction in PSP is less severe than in PD but remains clinically significant[@hawkes1997]:
- Prevalence: 40-60% of PSP patients demonstrate olfactory impairment
- Pattern difference: Unlike PD, PSP shows relatively preserved odor identification with impaired discrimination
- Anatomical basis: Olfactory bulb involvement reflects the broader tau pathology affecting brainstem structures
- Diagnostic utility: May help distinguish PSP from PD in uncertain cases
Olfactory Dysfunction in Multiple System Atrophy
MSA shows olfactory dysfunction similar to PD[@hawkes1997]:
- Prevalence: Approximately 60-70% of MSA patients demonstrate olfactory impairment
- Pattern overlap: Similar to PD, with both identification and discrimination affected
- Differentiation challenges: Olfactory testing alone cannot reliably distinguish MSA from PD
- Combined biomarkers: May be useful in multi-marker panels
Biomarkers Across Sample Compartments
Olfactory Mucosa Biomarkers
The olfactory mucosa contains olfactory receptor neurons (ORNs) that project directly to the brain, making it an attractive source of CNS biomarkers[@cecele2022]:
Alpha-Synuclein
- Aggregated α-syn: Detectable in olfactory mucosa of PD patients
- Seed activity: Tissue-based seeding assays show presence of pathological α-syn
- Diagnostic sensitivity: Variable across studies (50-80%)
- Specificity: Lower specificity due to presence in other conditions
- Sampling considerations: Requires specialized olfactory swab techniques
Tau Protein
- Total tau: Elevated in neurodegenerative conditions
- Phosphorylated tau: Specific patterns in tauopathies like PSP
- Olfactory bulb pathology: Shows tau pathology in PSP and AD
- Correlation with disease: Levels may reflect disease burden
Inflammatory Markers
- Cytokines: IL-6, TNF-α detectable in olfactory mucosa
- Microglial markers: Reflect neuroinflammatory processes
- Diagnostic value: May indicate disease-specific inflammation patterns
Blood-Based Biomarkers
Blood sampling offers a minimally invasive approach to biomarker detection:
Neurofilament Light Chain (NfL)
- Axonal damage marker: Released upon axonal injury
- Elevated in PSP: Higher than in PD or controls
- Prognostic value: Correlates with disease progression
- Clinical utility: Approved for clinical use in some contexts
Alpha-Synuclein Seeds
- Seed amplification: RT-QuIC and PMCA detect pathological α-syn
- Sensitivity: High sensitivity for synucleinopathies
- Specificity: Differentiates PD from controls
- Blood-brain barrier: Challenging but achievable detection
Inflammatory Markers
- Cytokines: TNF-α, IL-1β, IL-6 commonly elevated
- Chemokines: CCL2, CXCL10 implicated
- Microglial markers: sTREM2 in CSF, limited in blood
Urine-Based Biomarkers
Urine offers a completely non-invasive sampling option:
Alpha-Synuclein Species
- Oligomeric α-syn: Toxic species detectable in urine
- Oxidative modifications: Reflect oxidative stress in neurons
- Correlation studies: Variable correlation with disease state
Oxidative Stress Markers
- 8-OHdG: DNA oxidation product
- Isoprostanes: Lipid peroxidation markers
- Limited specificity: Elevated in many conditions
- Iron accumulation: Elevated in PD substantia nigra
- Urine levels: May reflect systemic accumulation
- Diagnostic value: Under investigation
Study Design and Methodology
Sample Collection Protocol
The study employs standardized collection protocols across all sample types:
Olfactory Mucosa Collection
Patient preparation: Nasal examination to rule out local pathology
Sampling location: Middle turbinate or olfactory cleft
Collection device: Specialized cotton or nylon swabs
Processing: Immediate freezing at -80°C
Quality control: RNA integrity for molecular analysesBlood Collection
Fasting state: Standardized collection timing
Collection tubes: EDTA, heparin, and SST tubes
Processing: Centrifugation within 2 hours
Storage: Plasma/serum at -80°C
Additional samples: PBMCs for cellular analysesUrine Collection
Standardized timing: Morning void preferred
Collection method: Mid-stream clean catch
Processing: Aliquoting within 4 hours
Creatinine normalization: For concentration comparisons
Storage: Multiple aliquots at -80°CAnalytical Approaches
The study employs multiple analytical platforms:
| Platform | Target Analytes | Advantages |
|----------|----------------|------------|
| ELISA | Proteins, antibodies | High throughput, validated |
| Simoa | Ultra-sensitive proteins | Detects low-abundance markers |
| RT-QuIC | Aggregated proteins | High sensitivity for seeds |
| Mass spectrometry | Metabolomics, proteomics | Unbiased discovery |
| qPCR | Nucleic acids | Genetic marker detection |
Clinical Applications and Utility
Early Detection Potential
The primary clinical utility lies in early disease detection[@postuma2015][@zhou2023]:
Prodromal identification: Patients with REM sleep behavior disorder (RBD) are at high risk
Pre-motor diagnosis: Smell testing could identify at-risk individuals
Disease modification: Early intervention opportunities
Clinical trial enrichment: Identification of early-stage patientsDifferential Diagnosis
Olfactory and systemic biomarkers may help differentiate between conditions:
- PD vs. PSP: Different patterns of olfactory loss and biomarker profiles
- PD vs. MSA: NfL levels and α-syn seeding differ
- Atypical vs. typical Parkinsonism: Combined biomarker panels
- AD vs. DLB: Different tau and α-syn profiles
Disease Progression Monitoring
Biomarkers may serve as progression markers:
- NfL trajectories: Correlate with clinical decline
- Olfactory change: Smell testing progression correlation
- Therapeutic monitoring: Response biomarkers for clinical trials
Relevance to Specific Conditions
Parkinson's Disease
Early detection in PD is particularly important because[@hawkes1997][@zhou2023]:
- Pre-motor window: 5-10 years before diagnosis
- Neuroprotective trials: Early intervention may be more effective
- Dopaminergic preservation: Neurons lost by diagnosis
- Risk stratification: Family history and genetic risk
Progressive Supranuclear Palsy
PSP presents unique challenges addressed by this study:
- Rapid progression: 7-9 year median survival
- Diagnostic delay: Average 2-3 years from symptom onset
- Atypical presentations: Richardson syndrome vs. variant PSP
- Treatment urgency: Early intervention critical
Multiple System Atrophy
MSA biomarker development is crucial:
- Autonomic failure: Core diagnostic feature
- Differential from PD: Treatment and prognosis differ
- Progression markers: Need for objective measures
- Clinical trials: Patient selection and monitoring
Research Implications
Biomarker Validation Framework
The study contributes to biomarker validation following the ATN (Amyloid, Tau, Neurodegeneration) framework:
Analytical validation: Assay precision, accuracy, reproducibility
Clinical validation: Sensitivity, specificity, predictive values
Clinical utility: Impact on patient outcomes
Implementation: Feasibility, cost-effectivenessMulti-Modal Integration
Combining biomarkers across compartments enhances diagnostic accuracy:
- Complementary information: Different biological pathways
- Cross-validation: Independent biomarker confirmation
- Panel optimization: Weighted algorithms
- Machine learning: Pattern recognition approaches
Expected Outcomes and Clinical Impact
Anticipated Results
The study is expected to generate:
Validated biomarker panels: Multi-analyte combinations with high accuracy
Sensitivity comparisons: Best performing markers for each condition
Stage-specific profiles: Biomarkers for early vs. established disease
Implementation guidelines: Clinical deployment protocolsClinical Significance
Successful biomarker development would transform:
Diagnostic accuracy: Earlier and more accurate diagnosis
Clinical trial design: Enriched patient populations
Therapeutic development: Progression and response markers
Patient counseling: Prognostic information for patientsChallenges and Limitations
Technical Challenges
Olfactory sampling variability: Collection technique differences
Biomarker stability: Degradation during processing
Assay standardization: Inter-laboratory variation
Background noise: Age-related changes and comorbiditiesBiological Limitations
Disease heterogeneity: Variable biomarker expression
Stage dependence: Early vs. late disease differences
Medication effects: Treatment-induced changes
Comorbidities: Confounding conditionsCross-References
- [Olfactory Dysfunction in Parkinson's Disease](/mechanisms/parkinson-non-motor-symptoms)
- [Biomarkers in Parkinsonian Syndromes](/mechanisms/parkinson-biomarkers)
- [Alpha-Synuclein Detection Methods](/mechanisms/alpha-synuclein-detection)
- [Early Detection Biomarkers](/mechanisms/early-detection-biomarkers)
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy-psp)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Multiple System Atrophy](/diseases/multiple-system-atrophy-msa)
- [REM Sleep Behavior Disorder](/mechanisms/rem-sleep-behavior-disorder)
References
[NCT06846658 - Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Neurodegeneration](https://clinicaltrials.gov/study/NCT06846658)
[Hawkes CH, et al. Olfaction in neurodegenerative disease. QJM (1997)](https://pubmed.ncbi.nlm.nih.gov/9379076/)
[Postuma RB, et al. Validation of the REM Sleep Behavior Disorder Screening Questionnaire. Sleep Medicine (2015)](https://pubmed.ncbi.nlm.nih.gov/26035124/)
[Boeve BF, et al. Olfaction in REM sleep behavior disorder and Parkinson disease. Annals of Neurology (2020)](https://pubmed.ncbi.nlm.nih.gov/32428379/)
[Liu X, et al. Olfactory dysfunction in neurodegenerative diseases. Current Alzheimer Research (2015)](https://pubmed.ncbi.nlm.nih.gov/26577046/)
[Zhou Y, et al. Olfactory dysfunction predicts disease progression in Parkinson's disease. NPJ Parkinson's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37029192/)
[Cecele M, et al. Alpha-synuclein detection in olfactory mucosa for Parkinson's disease diagnosis. Journal of Parkinson's Disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35689012/)